Stocks Health care ARVN

NASDAQ · Health care

Arvinas, Inc. (ARVN)

Arvinas, Inc. brought in $316.7M of revenue over the twelve months to June 30, 2026, down 15.0% from a year earlier. Net income was $9.3M, a net margin of 2.9%. In fiscal 2025 capital spending exceeded operating cash flow by $275.7M. At June 30, 2026 it held $94.3M in cash against $500K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.

What Arvinas, Inc. does

Arvinas, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ARVN.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Where ARVN ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Arvinas, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 31, 2026
   Employee stock plan registration S-8
2. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
3. August 4, 2026
   Quarterly report 10-Q · period to June 30, 2026
4. August 4, 2026
   Quarterly results 8-K
5. June 25, 2026
   Shareholder vote results 8-K
6. June 22, 2026
   Executive or director change 8-K
7. June 16, 2026
   Other event 8-K
8. June 2, 2026
   Investor disclosure 8-K
9. May 12, 2026
   Quarterly results 8-K
10. May 12, 2026
    Material agreement 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 22, 2026. Insider transactions on SEC

Insider trades

What the people running Arvinas, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about ARVN

What does Arvinas, Inc. do?

Arvinas, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ARVN.

Is Arvinas, Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $9.3M on revenue of $316.7M, a net margin of 2.9%.

How much revenue does Arvinas, Inc. make?

Over the twelve months to June 30, 2026 Arvinas, Inc. reported revenue of $316.7M. That is 15.0% less than a year earlier.

When did Arvinas, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from September 22, 2026.

Similar companies

Compare ARVN with

Compare ARVN with any company

Follow ARVN

Get an email when Arvinas, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ARVN: get an email when it files

Where the numbers come from

Financial figures are the values Arvinas, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.